Abbott received approval from the FDA for a new tablet formulation of antiretroviral drug Norvir (ritonavir). The new tablets can be stored at room temperature and do not require refrigeration. Norvir is used in combination with other antiretroviral medications to treat HIV. All forms of Norvir, including the soft-gel capsule and liquid form, remain available in the U.S.

“Norvir has been a critical component of HIV treatment for many patients. The innovation behind the development of the Norvir tablet is the direct result of years of effort by Abbott scientists to address the needs of people living with HIV,” said Scott Brun, M.D., divisional vice president, infectious disease development, Global Pharmaceutical R&D, Abbott. “Abbott has been dedicated to finding new and more convenient ways for patients to manage their HIV through the development of novel diagnostics testing methods and medications for more than 20 years.”

The Norvir tablet was developed using Abbott’s Meltrex technology, a melt-extrusion process, making it more heat-stable.